ACP
ORIC icon

Acuta Capital Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Acuta Capital Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-96,000
Closed -$679K – 45
2024
Q2 		$679K Sell
96,000
-7,992
-8% -$71.5K 0.57% 26
2024
Q1 		$1.43M Buy
+103,992
New +$1.24M 0.93% 26

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acuta Capital Partners's ORIC Position: Q3 2024 in Review

Acuta Capital Partners sold out of Oric Pharmaceuticals (ORIC) in Q3 2024, closing a stake of 96,000 shares — an estimated $679K sold.

Acuta Capital Partners first reported a position in ORIC in Q1 2024 and held it in 2 quarters. The position peaked at $1.43M in Q1 2024. 122 funds tracked by Wall St. Rank hold ORIC as of Q3 2024.

  • Acuta Capital Partners reported no remaining Oric Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 96,000 Oric Pharmaceuticals shares in Q3 2024, an estimated $679K.
  • Acuta Capital Partners first reported a position in Oric Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Acuta Capital Partners's Oric Pharmaceuticals position peaked at $1.43M in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2024.

Based on Acuta Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.